Compare Ascendis Pharma A/S (ASND) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Tidewater Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Tidewater Inc trades at $74.37 (market cap $3.65B). The key difference: Ascendis Pharma A/S is far larger — about 4.9× Tidewater Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals.
| ASND | TDW | |
|---|---|---|
Market Cap | $17.74B | $3.65B |
Sector | Health | Utilities |
52-Week High | $277.18 | $91.12 |
52-Week Low | $163.32 | $46.32 |
Enterprise Value | $18.11B | $3.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Tidewater (TDW) trades at $73.37, up 3.84% with bullish technical signals from moving averages. The company maintains strong profitability with 22.16% net income margin and 24.03% ROE, though recent Q1 2026 earnings missed estimates. Valuation appears reasonable with P/E of 12.37 and EV/EBITDA of 9.15. Recent news includes FTAI Infrastructure's acquisition of Tidewater Logistics and mixed analyst sentiment.
The outlook remains cautiously optimistic given strong fundamentals but tempered by recent earnings misses. Investment opportunity lies in reasonable valuation and sector positioning, while risks include execution challenges and energy market volatility. Analyst consensus leans neutral with 61.54% hold ratings, suggesting balanced risk-reward profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
